ES2074562T3 - Anticuerpo monoclonal contra proteina c. - Google Patents

Anticuerpo monoclonal contra proteina c.

Info

Publication number
ES2074562T3
ES2074562T3 ES90902092T ES90902092T ES2074562T3 ES 2074562 T3 ES2074562 T3 ES 2074562T3 ES 90902092 T ES90902092 T ES 90902092T ES 90902092 T ES90902092 T ES 90902092T ES 2074562 T3 ES2074562 T3 ES 2074562T3
Authority
ES
Spain
Prior art keywords
protein
antibody
activation
isolation
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90902092T
Other languages
English (en)
Inventor
Charles T Esmon
Naomi L Esmon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Application granted granted Critical
Publication of ES2074562T3 publication Critical patent/ES2074562T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ANTICUERPO MONOCLONAL DEPENDIENTE DE CA2+ QUE SE UNE ESPECIFICAMENTE A UNA SECUENCIA ESPECIFICA DE DOCE PEPTIDOS (E D Q V D P R L I D G K) EN LA REGION DE ACTIVACION DE LA PROTEINA C. EL ANTICUERPO NO SE UNE A LA PROTEINA C ACTIVADA Y PUEDE USARSE PARA INHIBIR LA ACTIVACION DE LA PROTEINA C MEDIANTE TROMBINA-TROMBOMODULINA. EL ANTICUERPO PUEDE AISLARSE DEL CULTIVO DE CELULAS O FLUIDO DE ASCITIS EN GRANDES CANTIDADES POR CROMATOGRAFIA DE AFINIDAD CON CONDICIONES FAVORABLES USANDO EL PEPTIDO UNIDO A UN SUSTRATO INMOVILIZADO. EL ANTICUERPO TIENE CIERTO NUMERO DE USOS ESPECIFICOS EN EL AISLAMIENTO Y CARACTERIZACION DE LA PROTEINA C Y COMO MODELO DE DISEÑO DE ANTICUERPOS DEPENDIENTES DE CA2+ PARA EL AISLAMIENTO DE OTRAS PROTEINAS, COMO DIAGNOSIS Y COMO TERAPIA PARA PREVENIR LA ACTIVACION DE LA PROTEINA C. LA PROTEINA C PUEDE PRODUCIRSE NATURALMENTE O MEDIANTE LA EXPRESION DEL GEN RECOMBINANTE. ENTRE LAS VENTAJAS DEL ANTICUERPO EN LA PURIFICIACION DE LA PROTEINA C SE INCLUYEN LA ESPECIFICIDAD PARA LA PROTEINA C Y LA PROTEINA C NO ACTIVADA, Y LA ESPECIFICIDAD DE LA UNION UNICA DE CA2+-PEPTIDO QUE PERMITE QUE EL LUGAR DE UNION QUEDE PROTEGIDO CUANDO SE INMOVILICE EN EL SOPORTE CROMATOGRAFICO. "IN VIVO" SE HA DEMOSTRADO QUE EL ANTICUERPO INHIBE EL CRECIMIENTO DE TUMORES. EL ANTICUERPO PUEDE UTILIZARSE TAMBIEN PARA ACTIVAR LA COAGULACION EN PACIENTES CON ALTOS NIVELES DE INHIBIDORES DE FACTOR VIII.
ES90902092T 1988-12-30 1989-12-28 Anticuerpo monoclonal contra proteina c. Expired - Lifetime ES2074562T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29244788A 1988-12-30 1988-12-30

Publications (1)

Publication Number Publication Date
ES2074562T3 true ES2074562T3 (es) 1995-09-16

Family

ID=23124711

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90902092T Expired - Lifetime ES2074562T3 (es) 1988-12-30 1989-12-28 Anticuerpo monoclonal contra proteina c.

Country Status (11)

Country Link
EP (1) EP0407544B1 (es)
JP (1) JP2559537B2 (es)
KR (1) KR940002033B1 (es)
AT (1) ATE122057T1 (es)
AU (2) AU641634B2 (es)
CA (1) CA2006684C (es)
DE (1) DE68922491T2 (es)
DK (1) DK171826B1 (es)
ES (1) ES2074562T3 (es)
FI (1) FI101476B1 (es)
WO (1) WO1990007524A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
WO1994002172A1 (en) * 1992-07-24 1994-02-03 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
JP3735112B2 (ja) * 1992-08-27 2006-01-18 ステイヒテイング・セントラール・ラボラトリウム・バン・デ・ブレドトランスフシーデイーンスト・バン・ヘト・ネーデルランドセ・ロデ・クルイス 凝血性蛋白質に特異的な抗体、未変性蛋白質を単離するためのそれらの利用、その蛋白質の蛋白質分解性開裂産物を含まない凝血性組成物
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5532136A (en) * 1993-06-22 1996-07-02 Bionebraska, Inc. Monoclonal antibody assay and kit for detecting metal cations in body fluids
US5840858A (en) * 1993-07-09 1998-11-24 T Cell Sciences, Inc. Protein purification using immobilized metal affinity chromatography for complement receptor proteins
HRP940645A2 (en) * 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
WO1995034652A1 (en) * 1994-06-10 1995-12-21 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein c
TW200407335A (en) * 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
KR20220162801A (ko) 2008-04-11 2022-12-08 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2647706B1 (en) * 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
US20160229922A1 (en) * 2013-09-20 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Treatment for hemorrhagic diseases by anti-protein-c antibody
KR102515796B1 (ko) 2014-12-19 2023-03-30 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 그의 사용 방법
KR20180054923A (ko) 2014-12-19 2018-05-24 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use

Also Published As

Publication number Publication date
AU669540B2 (en) 1996-06-13
DK209090A (da) 1990-08-30
FI904262A0 (fi) 1990-08-29
WO1990007524A1 (en) 1990-07-12
EP0407544A1 (en) 1991-01-16
FI101476B (fi) 1998-06-30
KR910700266A (ko) 1991-03-14
AU4968390A (en) 1990-08-01
DK171826B1 (da) 1997-06-23
DE68922491D1 (de) 1995-06-08
DE68922491T2 (de) 1995-11-09
JPH03504332A (ja) 1991-09-26
AU4422893A (en) 1994-01-27
ATE122057T1 (de) 1995-05-15
EP0407544B1 (en) 1995-05-03
JP2559537B2 (ja) 1996-12-04
AU641634B2 (en) 1993-09-30
FI101476B1 (fi) 1998-06-30
CA2006684A1 (en) 1990-06-30
DK209090D0 (da) 1990-08-30
KR940002033B1 (ko) 1994-03-14
CA2006684C (en) 1996-12-17

Similar Documents

Publication Publication Date Title
ES2074562T3 (es) Anticuerpo monoclonal contra proteina c.
Thompson et al. Purification of eukaryotic RNA polymerase II by immunoaffinity chromatography. Elution of active enzyme with protein stabilizing agents from a polyol-responsive monoclonal antibody.
EP0930366A3 (en) Binding domains in delta proteins
BG60256B1 (bg) Рекомбинантен метод за получаване на лимфотоксин
RU94045919A (ru) Антитела, клетки, полипептид, днк векторы, способ получения полипептида, способ получения антитела, фармацевтическая композиция
ATE132197T1 (de) Monoklonale antikörper
NZ504752A (en) Hydrophobically-modified protein compositions (particularly hedgehog proteins)
Singh et al. Different forms of human liver glutathione S-transferases arise from dimeric combinations of at least four immunologically and functionally distinct subunits
DE69435020D1 (en) Protein-tyrosin-phosphatase ptp-s31
Duriez et al. Characterization of anti-peptide antibodies directed towards the automodification domain and apoptotic fragment of poly (ADP-ribose) polymerase
DE69535855D1 (de) Calciumbindende rekombinante antikörper gegen protein c
Abraha et al. The preparation and characterization of monoclonal antibodies to human complement component C8 and their use in purification of C8 and C8 subunits
Barnes et al. Glass-bead affinity chromatography of cell attachment and spreading-promoting factors of human serum
Woodley et al. Specific identification of tissue kallikrein in exocrine tissues and in cell-free translation products with monoclonal antibodies
Arlaud et al. Use of an IgG fragment prepared with particulate plasmin to study the C1 binding and activation
NO903788L (no) Monoklonalt antistoff mot protein c.
Zibirre et al. Detection and localization of a cytoplasmic domain on the beta-subunit of Na+, K+-ATPase. A monoclonal antibody study.
Solomon et al. Affinity purification of antibodies using immobilized FB domain of protein A
ATE134218T1 (de) Methode zur reinigung rekombinanter t-pa von den ihren entsprechenden wirtszellproteinen
Werrbach-Perez et al. De novo synthesis of NGF subunits in S-180 mouse sarcoma cell line
Mannhalter Purification of plasma protein
Ratliff et al. Immunologic evidence for structural homology between the release factors of Escherichia coli
WO2000017363A3 (en) Interleukin-1 like molecule: interleukin-1-zeta; nucleic acids, polypeptides, antibodies, their uses
Shupp-Byrne et al. “Embryonic” Collagen (Type I Trimer) α1-Chains are Genetically Distinct from Type I Collagens α1-Chains
Woodley DEVELOPMENT AND CHARACTERIZATION OF MONOCLONAL ANTIBODIES TO RAT TISSUE KALLIKREIN AND THEIR USE IN BIOCHEMICAL AND IMMUNOHISTOCHEMICAL STUDIES (DIISOPROPYLPHOSPHO-FLUORIDATE, WESTERN BLOTTING, CELL-FREE TRANSLATION)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 407544

Country of ref document: ES